Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1

Interventions

Lenalidomide 3Melphalan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Bortezomib 2sargramostim 1ixazomib 1fludarabine phosphate 1fludarabine 1Voriconazole 1Thalidomide 1Sugars 1Stem Cell Transplantation 1Platelet Transfusion 1Leukapheresis 1Fluconazole 1Cyclophosphamide 1Colony-Stimulating Factors 1Calcium Dobesilate 1Bone Marrow Transplantation 1Blood Specimen Collection 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Diseases × ixazomib × Clear all
NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
57 enrolled 22 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡